Phosphoproteomics Molecular Tumor Board, Guest lecture March 19, 15.30 by Dr. Annika Schneider
- Post by: OPL
- March 11, 2025
- Comments off
Phosphoproteome profiling for clinical decision-making in molecular tumor boards
Dr. Annika Schneider
Technische Universität München
When: March 19 2025, 15.30- 16.30
Venue: Lecture Hall, RDC-Adore Research Building, Amsterdam UMC
Host: Connie Jimenez
Abstract Precision oncology approaches employing genomics-guided targeted therapy selection for individual cancer patients have provided substantial survival benefits in relatively small groups of patients. Because oncogenic mechanisms and signaling pathways manifest at the protein level, extending molecular diagnostics to the phosphoproteome is a logical next step. Analyzing 1800 tumor tissue samples from patients enrolled in the national precision oncology programs NCT/DKTK MASTER, INFORM, and CATCH for adults and children, respectively, we show that comprehensive phosphoproteome profiling is feasible and informative in a real-world prospective molecular tumor board (MTB) setting. We developed a tumor proteome activity status (TOPAS) scoring methodology that measures dysregulated receptor tyrosine kinase (RTK) signaling in individual patients and the TOPAS platform, an end-to-end data analysis system that condenses terabytes of raw data into patient-specific reports for MTB discussion. Discussing > 1000 phosphoproteome profiles in molecular tumor boards, we illustrate how TOPAS scoring can enhance therapeutic recommendations in MTBs. Additionally, our findings reveal novel potential cancer vulnerabilities, resistance mechanisms, and context-dependent oncogenic features that may be exploited therapeutically.
Biosketch Annika Schneider (*1991) studied molecular biology/molecular biotechnology (2010-2015) in Rostock and Munich. She did her PhD (2016-2021) at the Institute of Molecular Immunology at University hospital rechts der Isar in Munich focusing on the understanding and perturbation of T cell exhaustion in chronic viral diseases. In 2021, she started as a postdoc at the Chair of Proteomics and Bioanalytics led by Prof. Bernhard Küster, focusing on the understanding and accurate detection of aberrant cellular signaling in individual cancer patients using comprehensive (phospho)proteome profiling. Since 2022, she is heading the clinical proteomics group at the Chair of Proteomics and Bioanalytics focusing on the clinical translation of phosphoproteome profiling for enhanced cancer diagnostics in Germany.
*For those who cannot enter the RDC building, we will pick you up at 15.15 and 15.20 in the Atrium